Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Retained Earnings (2024 - 2025)

Xilio Therapeutics' Retained Earnings history spans 2 years, with the latest figure at -$429.1 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 15.77% year-over-year to -$429.1 million; the TTM value through Sep 2025 reached -$429.1 million, down 15.77%, while the annual FY2024 figure was -$383.8 million, N/A changed from the prior year.
  • Retained Earnings for Q3 2025 was -$429.1 million at Xilio Therapeutics, down from -$412.9 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$342.7 million in Q1 2024 and bottomed at -$429.1 million in Q3 2025.